DalCor Pharmaceuticals Licenses a Late-Stage Investigational Cardiovascular Drug Following Major Discovery by Montreal Heart Institute (MHI) Scientists
DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.
